We performed Kaplan-Meier analysis to determine whether serum changes in FGF19 and Ang-2 expression versus baseline are associated with PFS in patients with HCC receiving Lenvatinib treatment. This evidence concerns the gene FGF19 and hepatocellular carcinoma.